Meeting
2021 Genitourinary Cancers Symposium
Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC).
Authors
Bradley Alexander McGregor
Dana-Farber Cancer Institute, Boston, MA
Bradley Alexander McGregor , Elio Adib , Wanling Xie , Walter Michael Stadler , Yousef Zakharia , M Dror Michaelson , Ajjai Shivaram Alva , Subrina Farah , Amin Nassar , Lauren C Harshman , David J. Kwiatkowski , Rana R. McKay , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 306)
DOI
10.1200/JCO.2021.39.6_suppl.306
Abstract #
306
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
First Author: Andre Poisl Fay
Poster
2015 ASCO Annual Meeting
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
First Author: Andrea P. Myers
Poster
2012 ASCO Annual Meeting
Phase II study of everolimus (E) in refractory germ cell tumors (GCTs).
First Author: Michal Mego
Poster
2011 ASCO Annual Meeting
A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
First Author: E. Jonasch